[Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].
Biologic therapies able to induce or up-regulate anti-tumor immune responses could represent a complementary approach to improve the conventional treatment of squamous cell carcinomas of the head and neck (SCCHN). Patients with SCCHN are frequently immunocompromised due to the elimination and dysfunction of critical immune effector cells. Therefore, it might be necessary to restore these immune functions to allow for the generation of effective anti-tumor host responses. Simultaneously, to prevent tumor escape from immunological recognition and destruction, it might also be necessary to alter antigenic and immunogenic attributes of the malignant cells. The present overview summarizes general aspects, historical data, and recent advances in the field of immunotherapy of SCCHN, including non-specific immune stimulation, transfer of immunocompetent cells, gene therapy, use of monoclonal antibodies, and anti-cancer vaccines.
Hoffmann
T K
TK
Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten der Universität Düsseldorf. tkhoffmann@uni-duesseldorf.de
Whiteside
T L
TL
Bier
H
H
D019496:Cancer Vaccines / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends*; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D014611:Vaccination / Q000379:methods
D019496:Cancer Vaccines